ProCE Banner Activity

CME

Moving Toward a Cure for More Patients With Hodgkin Lymphoma: Expert Guidance and Practical Case Discussions

Multimedia
In this on-demand Webcast from a live symposium at ASH 2018, expert faculty review current best practices and emerging strategies for managing patients with Hodgkin lymphoma.

Physicians : maximum of 2.25 AMA PRA Category 1 {Credits}

Released: January 25, 2019

Expiration: January 24, 2020

No longer available for credit.

Share

Faculty

Robert W. Chen

Robert W. Chen, MD

Associate Professor
Department of Hematology
City of Hope
Duarte, California

Joseph M. Connors

Joseph M. Connors, MD, FRCPC

Clinical Professor (emeritus)
Centre for Lymphoid Cancer
BC Cancer and the University of British Columbia
Vancouver, Canada

Andrew M. Evens

Andrew M. Evens, DO, MSc, FACP

Professor and Chief
Division of Hematology/Oncology
Tufts Medical Center
Boston, Massachusetts

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by educational grants from

Seagen

Takeda Oncology

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with Hodgkin lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Choose optimal intensified frontline treatments for patients with advanced Hodgkin lymphoma considering the available clinical data and newly available treatment options
  • Explain the application and limitations of FDG-PET imaging in the early assessment of response to treatment in Hodgkin lymphoma
  • Plan therapeutic strategies to prevent second relapse after transplant in patients with Hodgkin lymphoma at risk of progression
  • Evaluate the clinical data on available and promising investigational agents for patients with relapsed/refractory Hodgkin lymphoma
  • Formulate therapeutic strategies for Hodgkin lymphoma that consider the optimal sequencing of brentuximab vedotin and immune checkpoint inhibitors

Disclosure

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Robert W. Chen, MD

Associate Professor
Department of Hematology
City of Hope
Duarte, California

Robert W. Chen, MD, has disclosed that he has received fees for non-CME/CE services from Merck and Seattle Genetics and consulting fees from Bristol-Myers Squibb, Merck, and Seattle Genetics.

Joseph M. Connors, MD, FRCPC

Clinical Professor (emeritus)
Centre for Lymphoid Cancer
BC Cancer and the University of British Columbia
Vancouver, Canada

Joseph M. Connors, MD, FRCPC, has disclosed that he has received consulting fees from Seattle Genetics.

Andrew M. Evens, DO, MSc, FACP

Professor and Chief
Division of Hematology/Oncology
Tufts Medical Center
Boston, Massachusetts

Andrew M. Evens, DO, MSc, FACP, has disclosed that he has received consulting fees from AbbVie, Acerta, Affimed, Bayer, Janssen, Pharmacyclics, and Seattle Genetics.

Staff Disclosure

Staff

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no real or apparent conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

The PIM planners and managers have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 2.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 25, 2019, through January 24, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in and performance at selecting treatment for individual patients with Hodgkin lymphoma.